Literature DB >> 12144897

Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.

Ulrich R Hengge1, Thomas Ruzicka, Stephen K Tyring, Martin Stuschke, Michael Roggendorf, Robert A Schwartz, Siegfried Seeber.   

Abstract

The pathogenesis of Kaposi's sarcoma (KS) is better understood since the identification of the novel human herpesvirus 8 (HHV8), which can be found in all forms of KS. Viral oncogenesis and cytokine-induced growth, as well as some states of immunocompromise, contribute to its development. Several virally encoded genes--eg, bcl-2, interleukin 6, cyclin D, G-protein-coupled receptor, and interferon regulatory factor--provide key functions on cellular proliferation and survival. Growth promotion of KS is further stimulated by various proinflammatory cytokines and growth factors such as tumour necrosis factor a, interleukin 6, basic fibroblast growth factor, and vascular endothelial growth factor, resulting in a hyperplastic polyclonal lesion with predominant spindle cells derived from lymphoid endothelia. HHV8 has recently been discovered to escape HLA-class-I-restricted antigen presentation to cytotoxic T lymphocytes by increasing endocytosis of MHC class I chains from the cell surface, thus enabling latent infection and immune escape in primary and chronic infection. Multicentric Castleman's disease is a rare lymphoproliferative disorder of the plasma cell type, which has been reported in both HIV-seropositive and HIV-seronegative patients, and which frequently contains HHV8 DNA. Pleural effusion lymphoma, or body-cavity-based lymphoma, belongs to the group of non-Hodgkin B-cell lymphomas characterised by pleural, pericardial, or peritoneal lymphomatous effusions in the absence of a solid tumour mass. Pleural effusion lymphoma has an intermediate immunophenotype lacking B or T lymphocyte antigens and also belongs to the diseases associated with HHV8.

Entities:  

Mesh:

Year:  2002        PMID: 12144897     DOI: 10.1016/s1473-3099(02)00288-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  44 in total

1.  Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.

Authors:  Tammy M Rickabaugh; Helen J Brown; DeeAnn Martinez-Guzman; Ting-Ting Wu; Leming Tong; Fuqu Yu; Steven Cole; Ren Sun
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Regulation of CD1d expression and function by a herpesvirus infection.

Authors:  David Jesse Sanchez; Jenny E Gumperz; Don Ganem
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

3.  Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.

Authors:  Sofia Corte-Real; Chris Collins; Frederico Aires da Silva; J Pedro Simas; Carlos F Barbas; Yuan Chang; Patrick Moore; Joao Goncalves
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

4.  [Classical Kaposi's sarcoma in a 78-year-old woman].

Authors:  A S Antal; B Homey; J Reifenberger; U R Hengge
Journal:  Hautarzt       Date:  2008-04       Impact factor: 0.751

5.  Surgical Management of Unicentric Castleman's Disease in the Abdomen.

Authors:  Min-Sang Kim; Jae-Kyun Ju; Young Kim
Journal:  Ann Coloproctol       Date:  2014-04-25

Review 6.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

7.  Induction of angiogenic chemokine CCL2 by human herpesvirus 8 chemokine receptor.

Authors:  Young Bong Choi; John Nicholas
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

8.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 9.  The role of stromal-derived factor-1--CXCR7 axis in development and cancer.

Authors:  Radoslaw B Maksym; Maciej Tarnowski; Katarzyna Grymula; Joanna Tarnowska; Marcin Wysoczynski; Riu Liu; Boguslaw Czerny; Janina Ratajczak; Magda Kucia; Mariusz Z Ratajczak
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

10.  The malignant potential of HIV-associated Kaposi sarcoma.

Authors:  Neil H Wood; Liviu Feller
Journal:  Cancer Cell Int       Date:  2008-10-31       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.